Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent NSCLC~* PDL1-positive status as determined by an immunohistochemistry assay performed by a central laboratory. A positive result in chemotherapy, chemoradiation of the tumor sample biopsy will satisfy the eligibility criterion~* Eastern Cooperative Oncology group Performance Status of 0 or 1~* Life expectancy greater than or equal to 12 weeks~* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors Version 1.1~* Adequate hematologic and end organ function~Exclusion Criteria:~* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exceptions are allowed. Hormone-replacement therapy or oral contraceptives, and tyrosine kinase inhibitors approved for treatment of NSCLC discontinued greater than 7 days prior to Cycle 1 Day 1~* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment~* Known central nervous system disease, including treated brain metastases in the following participants:~  1. who will not receive prior chemotherapy for advanced disease~ 2. who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (referred as 2L+ participants)~* Participants with a history of treated asymptomatic brain metastases are allowed in the 2L+ participants and previously treated for brain metastases.~* Leptomeningeal disease~* Uncontrolled tumor-related pain~* Uncontrolled hypercalcemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (MPDL3280): 1L Participants (Type: EXPERIMENTAL): Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
- Atezolizumab (MPDL3280): 2L+ Participants (Type: EXPERIMENTAL): Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
- Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants (Type: EXPERIMENTAL): Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete